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Abstract
Infections of humans and livestock with African trypanosomes are treated with drugs intro-
duced decades ago that are not always fully effective and often have severe side effects.
Here, the trypanosome haptoglobin-haemoglobin receptor (HpHbR) has been exploited as
a route of uptake for an antibody-drug conjugate (ADC) that is completely effective against
Trypanosoma brucei in the standard mouse model of infection. Recombinant human anti-
HpHbR monoclonal antibodies were isolated and shown to be internalised in a receptor-
dependent manner. Antibodies were conjugated to a pyrrolobenzodiazepine (PBD) toxin
and killed T. brucei in vitro at picomolar concentrations. A single therapeutic dose (0.25 mg/
kg) of a HpHbR antibody-PBD conjugate completely cured a T. brucei mouse infection
within 2 days with no re-emergence of infection over a subsequent time course of 77 days.
These experiments provide a demonstration of how ADCs can be exploited to treat proto-
zoal diseases that desperately require new therapeutics.
Author summary
Here we show that antibody-drug conjugates (ADCs) can be re-purposed from cancer
immunotherapeutics to anti-protozoals by changing the specificity of the immunoglobu-
lin to target a trypanosome cell surface receptor. Trypanosomes were used as a model sys-
tem due to the availability of receptor null cell lines that allowed the unambiguous
demonstration that ADCs targeted to a parasite surface receptor could be specifically
internalised via receptor-mediated endocytosis. A single low dose of the resulting ADC
was able to cure a stage 1 mouse model of trypanosome infection. We have used toxins
and conjugation chemistry that are identical to anti-cancer ADCs demonstrating the
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ability to piggy-back onto the huge research efforts and resources that are being invested
in the development of such ADCs.
The potential for development of ADCs against a wide range of human pathogens is
vast, where only epitope binding sites need vary in order to provide selectivity. This pro-
vides a far-reaching opportunity for the rapid development of novel anti-protozoals for
the targeted killing of a wide range of pathogens that cause disease worldwide, especially
in developing countries.
Introduction
Infection with African trypanosomes causes disease in humans, livestock and wild animals. At
least seven species are able to infect livestock but only Trypanosoma brucei subspecies normally
infect humans: T. b. gambiense and T. b. rhodesiense cause chronic or acute Human African
Trypanosomiasis (HAT) respectively [1]. New drug treatments are required for human treat-
ment, the drugs currently used require multiple administrations over periods of weeks and all
can have severe side effects (reviewed in [2–4]).
Without intervention, infection persists as the trypanosomes have evolved a population sur-
vival strategy based on antigenic variation of the variant surface glycoprotein (VSG) that is
present as a densely packed coat on the external face of the plasma membrane. Receptors for
host nutrient macromolecules are integrated in the VSG coat, such as the HpHbR which is
involved in haem acquisition through binding and subsequent endocytosis of host haptoglo-
bin-haemoglobin[5]. Primate-specific innate immune protein complexes have evolved to
exploit this nutrient uptake and kill most isolates of T. brucei [5]. The two complexes, Try-
panosome Lytic Factor 1 and 2 (TLF1 and TLF2), each contain two primate-specific proteins,
apolipoprotein L1 (apoL-1) [6] and haptoglobin-related protein bound to haemoglobin
(HprHb) which acts as a molecular mimic of HpHb[7–10]. HpHbR binds and internalises
TLF1 and apoL-1 kills the trypanosome [5, 11]. Human infective trypanosomes have evolved
counter-measures to the TLFs, but this has not included deletion of the HpHbR [12–19].
The binding of a host macromolecule to a receptor, followed by the internalisation of the
complex, provides a potential route to specifically deliver therapeutics into trypanosome cells.
Entry of TLF1 via the HpHbR and the release of apoL-1 after internalisation is analogous to
the mode of action of ADCs [20], a growing class of therapeutics, particularly used in applica-
tions in oncology[21–23] and also with demonstrated potential as anti-bacterials[24, 25]. An
early attempt to develop ADCs against the intracellular American trypanosome, Trypanosoma
cruzi, used chlorambucil conjugated to polyclonal IgGs purified from chronically infected rab-
bits [26] and, while results were promising, this was only partially successful. More recently,
antibody therapeutics against African trypanosomes based on single domain antibodies
derived from camelid immunoglobulins (nanobodies) recognising some, but not all, VSGs
[27, 28] have also been developed. One study used a nanobody apoL-1 fusion protein that was
curative in mouse infections[29]. In another two studies, nanobodies were used to create nano-
particles containing pentamidine, one of the current drugs used to treat trypanosome infec-
tion. These particles bound VSG and were successfully taken up into the endocytic pathway,
the concentration required for cure was 10 to 100-fold lower than free pentamidine over a
course of four doses [30, 31]. However, the variability of the VSG molecules and underpinning
antigenic variation will almost certainly limit their effectiveness as targets for therapeutic
delivery.
ADC cures stage 1 animal trypanosomiasis
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Here we have developed a recombinant human anti-trypanosome-HpHbR antibody conju-
gated to a PBD toxin, selected so that recognition of the trypanosome would be independent
of the VSG identity. This approach also strategically exploits advances in anti-cancer ADC
development. The antibody-PBD conjugate was effective at killing trypanosomes in culture at
picomolar concentrations whereas killing of human cell lines required more than 100,000-fold
higher concentrations. A single low dose (0.25 mg/kg) of one of the ADCs resulted in a long-
term cure in the standard mouse model of trypanosome infection[32, 33] with no apparent
adverse effects.
Results
HpHbR was chosen as a target for ADCs for two reasons: first it is responsible for receptor
mediated endocytosis of ligands larger than IgGs and structural information suggested it is
accessible to external antibodies [34, 35]; second, a cell line with both HpHbR alleles deleted
(HpHbR -/-) was available as a control for specificity. HpHbR -/- cell lines have little or no
growth phenotype in culture [5, 34], although they are attenuated in the murine experimental
model of infection [5].
Identification of single chain variable fragments recognising the N-
terminal domain of the haptoglobin-haemoglobin receptor
In T. brucei, the mature HpHbR has a large N-terminal domain (264 residues) that contains
the HpHb binding site [34] and a small C-terminal domain (79 residues) attached to the
plasma membrane by a glycosylphosphatidylinositol anchor. Recombinant HpHbR N-termi-
nal domain [34] was used for phage display affinity selection from a single chain variable frag-
ment (scFv) library. Specificity for HpHbR was confirmed using phage ELISA and sixteen
distinct scFvs were identified (Fig 1A).
Fig 1. The generation of ADCs that target the T. brucei HpHbR. (A) Workflow for the generation of anti-trypanosomal ADCs. (B) Structures of the two
PBD toxins (SG3199 and SG3552) and their corresponding toxins plus linker derivatives (SG3249 and SG3376) used in this study. Note that the linker of
SG3249 contains a cleavable dipeptide motif whereas the linker of SG3376 does not.
https://doi.org/10.1371/journal.pntd.0007373.g001
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HpHbR antibodies are internalised by receptor mediated endocytosis
Six of the scFvs (S1 Fig) were reformatted as human IgG1 for further analysis. To determine
whether any of these IgGs were endocytosed by trypanosomes in a receptor dependent man-
ner, each was labelled with Alexa fluor-594 and incubated with either Trypanosoma brucei,
Lister 427, HpHbR wild-type or HpHbR -/- cells in culture for 2 hours in the presence of the
lysosomal protease inhibitor FMK-024. A control IgG1 with an unrelated specificity (NIP228)
was used in parallel. Internalisation was monitored by microscopy (Fig 2) and at 10 nM IgG1
five of the six HpHbR antibodies were endocytosed by wild-type cells but not by HpHbR-/-
cells and localised to a compartment consistent with the lysosome. There was no internalisa-
tion of the control antibody in either cell line at 10 nM. Hence, five of the antibodies were
internalised by receptor mediated endocytosis demonstrating that they recognised epitopes on
HpHbR that are accessible on live cells. The sixth HpHbR antibody (Tb086) showed limited
internalisation and was not used further.
Fig 2. Receptor mediated endocytosis of humanised anti-HpHbR IgG1s. Uptake of Alexa594-labelled antibodies into T. b. brucei Lister 427 HpHbR wild
type and -/- cells was monitored by microscopy. Uptake of five of the seven selected antibodies was detected at 10 nM in wild-type (indicated by arrows in
upper panel) but not in HpHbR -/- cells (lower panel). No specific uptake of the remaining antibody (Tb086) or a control antibody (NIP228) was detected.
Scale bar represents 10 μm.
https://doi.org/10.1371/journal.pntd.0007373.g002
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Toxin-conjugated HpHbR-targeting antibodies kill trypanosomes at
picomolar concentrations
The receptor-mediated endocytosis of these HpHbR antibodies was then exploited to assess
the effectiveness of ADCs against T. brucei in vitro. Two PBDs, SG3199 and SG3552 (ref[36])
(Fig 1B), were used in these experiments; each was used as a toxin-linker derivative, SG3249
and SG3376 respectively (Fig 1B), for antibody conjugation. PBDs are DNA minor groove
binding toxins [37–40] and were chosen as trypanosomes have a highly complex mitochon-
drial genome formed from a network of thousands of concatenated DNA circles and are con-
sequently susceptible to DNA binding toxins. This sensitivity is illustrated by the original
patent on ethidium bromide as a treatment for trypanosome infection and ethidium deriva-
tives are still used for animal trypanosomiasis [41, 42].
To assay for trypanocidal activity, cultures of T. brucei were incubated with a range of con-
centrations of the anti-HpHbR-PBD conjugates over 48 hours. Growth was measured as per-
centage proliferation compared to no treatment, with 0% relative to controls representing no
viable cells observed, and IC50 values calculated.
Initial experiments were designed to identify the most effective HpHbR antibody and used
the PBD, SG3199. Free SG3199 had an IC50 of ~1 pM (Fig 3A, S1 Table), this confirmed its
toxicity towards trypanosomes and indicated that it is freely cell permeable. Prior to conjuga-
tion to the IgGs, SG3199 was modified by the addition of a linker to facilitate conjugation and
release in the lysosome after proteolysis to produce SG3249[43] (Fig 1B). Free SG3249 had an
IC50 of ~240 pM (Fig 3A, S1 Table); presumably the hydrophilic nature of the linker meant
that cell access via passive diffusion was reduced. Antibody-SG3249 conjugates were prepared
for the five HpHbR antibodies selected in the uptake experiment above and the NIP228 IgG
control, following IgG engineering to contain a surface exposed cysteine residue at position
239 in the heavy chain CH2 domain for conjugation to PBD molecules[44] (Fig 1B). The
HpHbR antibody-SG3249 conjugates all killed trypanosomes with IC50 values between 9 and
86 pM compared to 2100 pM for the control NIP228-SG3249 conjugate (Fig 3A and S1 Table),
demonstrating targeted cell killing by HpHbR antibody-PBD conjugates. The two most potent
antibodies were Tb074 and Tb085 with IC50 values of 17 and 9 pM respectively and they were
selected for further experiments.
The next set of experiments used PBD SG3552 and its linker-derivative SG3376 [45, 46]
(Fig 1B). This toxin-linker combination was chosen as it was designed to have fewer off-target
effects [45, 47] and was shown to be more potent against trypanosomes in preliminary experi-
ments. Three antibody-SG3376 conjugates were prepared from Tb074, Tb085 and NIP228 and
all were tested for trypanocidal activity as above but using HpHbR wild type and -/- cell lines
(Fig 3B and Table 1). SG3552 killed trypanosomes with IC50 values of 0.14 pM in wild type
and 0.2 pM in HpHbR -/- cell lines; the addition of the linker to make SG3376 reduced the tox-
icity to 112 pM and 197 pM in wild type and -/- cell lines respectively, again presumably due
to the increase in hydrophilicity conferred by the linker reducing passive cell entry. The anti-
body conjugates Tb085-SG3376 and Tb074-SG3376 were effective in killing wild-type try-
panosomes with IC50 values of 0.3 pM and 1.3 pM respectively. In contrast both were far less
effective against HpHbR -/- cells with IC50 values of 1390 pM and 3270 pM showing that the
action of the ADC is dependent on HpHbR expression. The action of the NIP228-SG3376 con-
jugate was unaffected by HpHbR expression and had an IC50 of 3750 pM and 3000 pM in
HpHbR wild type and -/- cells respectively. Taken together these findings showed that HpHbR
antibody-SG3376 conjugates are highly effective in killing trypanosomes through a mechanism
whereby the presence of the receptor increases specificity by several thousand-fold over the
action of non-specific antibody-SG3376 conjugates.
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Fig 3. HpHbR antibody-PBD conjugates result in T. brucei cell death at low picomolar concentrations in vitro in a
HpHbR-dependent manner. (A) Toxin SG3199 kills T. b. brucei wild type cells at sub-picomolar concentrations (IC50
0.86 pM), killing activity is reduced by the addition of a linker (SG3249 IC50 236.0 pM). Conjugation of SG3249 to a
non-specific control antibody (NIP228) further reduces trypanosome killing activity to low nanomolar concentrations
(IC50 2.1 nM) whereas conjugation of SG3249 to antibodies that target the HpHbR increased killing activity to low
ADC cures stage 1 animal trypanosomiasis
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To assess whether the HpHbR antibody-SG3376 conjugates have specificity for trypano-
somes over mammalian cells in culture, PBD toxin SG3552 and antibody-SG3376 conjugates
were assessed for toxicity against a range of human cell lines. SG3552 was toxic to all cell lines
assayed at picomolar concentrations (S3 Fig), the most sensitive was the Jurkat cell lines with
an IC50 value of 19.6 pM, around 100-fold less-sensitive than the T. brucei cell lines (Table 1).
This was expected: trypanosomes are particularly sensitive to many DNA damaging toxins as
described above. The NIP228-SG3376, Tb074-SG3376 and Tb085-SG3376 conjugates all had
IC50 values that were conservatively estimated to be>50 000 pM (S3 Fig). The IC50 values of
the two HpHbR antibody-SG3376 conjugates for the human cell lines was at least 50,000 times
greater than those for trypanosomes (Table 1).
A single Tb085-SG3376 administration results in the clearance of
trypanosome infection in mice
Based on the specificity and potency observed in the above experiments, Tb085-SG3376 conju-
gate was chosen to determine anti-HpHbR-toxin conjugate efficacy in a mouse model of T. b.
brucei infection. Mice were infected with a pleomorphic trypanosome cell line, T. b. brucei
GVR35-VSL2, that expresses a luciferase transgene (PpyRE9h) to facilitate measurement of
infection in live animals over a prolonged time course using bioluminescence imaging (BLI)
[32, 33]. This method has the advantage that it detects trypanosomes in the bloodstream and
tissues. Fifteen mice were each infected with 3x104 trypanosomes and imaged on day 3 post
infection to provide a pre-treatment BLI signal level indicative of the whole-body infection
picomolar concentrations (IC50 values range from 86 pM for Tb073-SG3249 to 9.4 pM for Tb085-SG3249). All assays
were carried out in triplicate over 48 hours. Lines represents nonlinear regression lines of best fit on Log10 transformed
data. Error bars represent standard error of the mean (s.e.m.), n = 3 biological replicates (carried out in parallel). (B)
Toxin SG3552 kills T. b. brucei wild type and HpHbR -/- cells with sub-picomolar IC50 concentrations The IC50 is
increased by orders of magnitude by the addition of a linker (Table 1). Conjugation of SG3376 to a non-specific
control antibody (NIP228) further increases the IC50 to nanomolar concentrations in both trypanosome cell lines.
HpHbR antibody SG3376 conjugates have an IC50 in the low/sub picomolar range for wild type T. b. brucei. In
contrast, IC50 values with T. b. brucei HpHbR -/- cells remained similar to the control ADC. All assays were carried out
in triplicate over 48 hours. Lines represents nonlinear regression lines of best fit on Log10 transformed data. See Table 1
for corresponding IC50 values. Error bars represent s.e.m., n = 3 biological replicates (carried out in parallel).
https://doi.org/10.1371/journal.pntd.0007373.g003
Table 1. IC50 values (pM) of SG3552-based toxins and ADCs against T.brucei cell lines and a human Jurkat cell line. The IC50 values of toxin SG3552, toxin plus linker
SG3376, a control ADC (NIP228-SG3376) and two anti-trypanosome ADCs targeting the T. b. brucei HpHbR (Tb074-SG3376 and Tb085-SG3376) against T. b brucei wild
type and T. b brucei HpHb -/- (Fig 3B) were calculated. Values in bold are best-fit IC50 values, the range is the 95% confidence intervals. It was not possible to calculate
accurate IC50 values for the Jurkat cell line due to lack of saturation of the cell killing assay and so all were conservatively estimated as greater than 50 nM from the data in
S2 Fig. All values are shown to 3 significant figures.
IC50 (pM)
Cell line T. b. brucei T. b. brucei HpHbR -/- Human Jurkat
SG3552 0.14 0.195 19.6
Toxin (0.11–0.18) (0.14–0.27) (10.8–35.8)
SG3376 112 197 >50,000
Toxin plus linker (76.7–163) (145–268)
NIP228-SG3376 3750 3000 >50,000
Control (2610–5380) (2260–3960)
Tb074-SG3376 1.33 3270 >50,000
(1.16–1.53) (2400–4450)
Tb085-SG3376 0.297 1390 >50,000
(0.25–0.36) (1030–1880)
https://doi.org/10.1371/journal.pntd.0007373.t001
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burden measured as photons per second (p/s) after administration of luciferase substrate. All
infected mice had a total flux of between 2.5x109 and 5.9x109 p/s with the exception of a single
mouse which had a lower level of infection at 3x107 p/s. Subsequent to imaging, on day 3,
groups of five mice were then treated with (1) 0.25 mg/kg Tb085-SG3376 or (2) 0.25 mg/kg
NIP228-SG3376 or (3) PBS alone. Three uninfected mice were used as negative controls for
the BLI.
Infection levels were assessed by BLI on days 4, 5, 6 and 7, and then at regular further
time points (Fig 4, S4 and S5 Figs). Within the first day post-treatment the BLI signal in
Tb085-SG3376-treated mice had dropped 3-fold relative to the pre-treatment signal whilst
control mice (NIP228-SG3376 or PBS alone) had increased more than 2-fold. These control
mice remained infected with a BLI signal consistent with a first and second wave of parasitae-
mia, characteristic of trypanosome infection dynamics [48, 49]. At day 14 (11 days post-treat-
ment), control mice were culled at a humane endpoint, as the BLI signal represented a parasite
burden that would invariably lead to clinical symptoms of trypanosomiasis and death [33].
In contrast, the BLI signal in mice in group 1 (treated with Tb085-SG3376) had decreased
to the level of uninfected controls by 2 days post-treatment. The BLI signal remained indistin-
guishable from the uninfected controls for 60 days post-treatment and the mice continued to
appear healthy throughout the experiment, not showing any external symptoms of clinical try-
panosomiasis. To determine if Tb085-SG3376 treated mice were harbouring very small num-
bers of trypanosomes that were kept in check by the mouse adaptive immune response, the
mice were immunosuppressed with a single dose of cyclophosphamide on day 66 post-infec-
tion and BLI measurements made on days 69, 74, 76 and 80 post-infection; no trypanosomes
were detected (Fig 4, S4 and S5 Figs). On day 80 post-infection mice were culled and BLI was
performed on mouse tissues post-necropsy; again no trypanosomes were detected in any tissue
(S6 Fig). Finally, both a blood sample and a section of brain tissue from each of the five mice
treated with Tb085-SG3376 were incubated in trypanosome culture medium for one month;
in no case were any trypanosomes then detected. Together, these observations and measure-
ments indicate that a single dose of Tb085-SG3376 was sufficient to cure infection in 5/5 mice
in the experimental group.
Discussion
African trypanosomes proliferate in the bloodstream and tissue spaces of their mammalian
hosts where they are continually exposed to the adaptive immune response. The trypanosome
cell surface is covered by a densely packed coat of VSG that underpins persistence of infection
by antigenic variation. The VSG coat must be permissive for receptor mediated endocytosis of
host macromolecules as nutrients and here this has been exploited for the delivery of an ADC.
The HpHbR was chosen for this study as: (i) it is a natural route for uptake of the trypanolytic
factors [5], which kill sensitive trypanosomes strains in human serum; (ii) it is accessible to
ligands larger than IgG [5]; (iii) it has a known structure [34, 35]; (iv) HpHbR null cell lines
grow at a normal rate in culture [5, 34] and were an ideal control for specificity of uptake. We
found that HpHbR monoclonal antibodies are taken up into HpHbR wild type cells but not
HpHbR-/- cells, proving that receptors for host macromolecules are accessible on live trypano-
somes. These same antibodies conjugated to a PBD were able to kill trypanosomes in culture at
pM concentration in a manner that was dependent on HpHbR expression. Significantly higher
doses, were needed to kill a panel of mammalian cell lines. Finally, in the mouse model of
infection, a single administration of an anti-HpHbR ADC was sufficient to cure the infection.
The ADC effectively cleared an infection from mice that had been inoculated in the perito-
neum and so it is highly unlikely that the trypanosomes were restricted to the bloodstream.
ADC cures stage 1 animal trypanosomiasis
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Fig 4. A single low dose of Tb085-SG3376 was able to cure infection in a mouse model of trypanosomiasis. Three
groups of 5 mice were infected with pleomorphic T. b. brucei GVR35-VSL2 cells [32, 33], which allow for parasite
burden in live mice to be assessed over a time course by bioluminescent imaging (BLI). BLI was performed prior to
any treatment at 3 dpi and then at regular time points following treatment on 3 dpi with a single intravenous dose of
(1) 0.25 mg/kg Tb085-SG3376 (n = 5), (2) 0.25 mg/kg NIP228-SG3376 (n = 5) or (3) PBS alone (n = 5). Unlike the
ADC cures stage 1 animal trypanosomiasis
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Immunoglobulins, and ADCs, are systemically distributed and therefore have access to sites
outwith the bloodstream.
The findings here have validated an approach that builds on the considerable progress in
anti-cancer ADCs and repurposing into an anti-protozoal simply involves the development of
pathogen specific antibodies. The use of ADCs here was specifically based on those developed
in oncology. Currently, ADCs are used in the clinic against Hodgkin lymphoma (Brentuximab
vedotin) [22] and HER2-positive breast cancer (ado-trastuzumab-emtansine) [50]. Many oth-
ers are in pre-clinical development or clinical trials, including ADCs against a range of cancers
that incorporate PBDs, including SG3249, one of the toxins used in this study [51–53].
The success of the experiments above lead to the question of whether this is a realistic
approach for development of therapeutics for trypanosome and other protozoan infections.
Amongst the key challenges in generating ADCs for applications in oncology is ensuring mini-
mal off-target toxicity and so, as well as through ADC chemistry, low doses are desirable
(reviewed in [54]). The single dose of 0.25 mg/kg was selected in these experiments as a proof-
of-concept because it is at the lower end of effective oncological ADC treatment in mice [55]
and is well below the anticipated maximum tolerated dose [56]. The minimum efficacious
dose achievable with the anti-HpHbR ADC was not tested in this study and it is likely that the
targeting of parasites will be achieved using lower doses than required for oncology for two
key reasons. First, in contrast to the surface of cancer cells, which may not have tumour spe-
cific antigens, parasite-specific surface receptors are entirely different from host cell surface
receptors leading to highly selective uptake of the antibody into the pathogen. Second, the
effectiveness of the ADC in this study was enhanced by the sensitivity of trypanosomes to
DNA-binding agents, in comparison to host cells. Together these led to a 100,000-fold differ-
ence in toxicity between trypanosome and human cells in vitro. These considerations will also
apply to other protozoal pathogens providing a suitable target can be identified. We are not
proposing that the HpHbR ADC provides an immediate therapeutic, but it illustrates that the
approach is very effective and will improve as better receptor targets are trialled. Further, it
was straightforward to identify multiple suitable monoclonal HpHbR antibodies so it can be
anticipated that any escape through the appearance of polymorphisms in the receptor could
readily be countered by utilising an ADC that recognises a different epitope or even a different
receptor.
Disease caused by T. brucei infection has two stages: in stage 1 trypanosomes are excluded
from the central nervous system (CNS) by the blood brain barrier (BBB) while in stage 2 infec-
tions trypanosomes enter the CNS. In the experimental model used here, we have tested the
ability to clear a stage 1 infection. Would ADCs be able to target trypanosomes in the CNS?
While administered intravenous antibodies are present in the CNS at less than 0.1% of the
concentration in the blood in murine models [57, 58] increased BBB permeability has been
observed in murine models of neurological-stage trypanosomiasis [59–61], which will increase
control-treated mice, Tb085-SG3376 treatment caused a decrease in the luminescent signal to that obtained from
uninfected control animals within 2 days and this remained the case for the duration of the infection, including
following the immunosuppression of Tb085-SG3376 treated mice at 66 dpi. Mice treated with NIP228-SG3376 or
PBS were culled at a humane endpoint on day 14. (A) Quantification shown is the combined (dorsal + ventral)
luminescence over the whole mouse in photons per second (p/s). The corresponding quantification data from the 18
individual mice are shown in S5 Fig. Error bars represent standard deviation. Downward error bars are missing from 4
data points due to scale constraints. (B) For each group of mice selected ventral images for the BLI are shown.
Corresponding dorsal images of the same mice are shown in S4 Fig. The scale bar represents the photons emitted at
any given point on the image. Exposure times range from 0.5 seconds (for heavily burdened mice) to 5 minutes (for
uninfected animals). One mouse in the PBS control group had a lower BLI signal than all other infected mice at 3 dpi
(S5 Fig). In the image shown here this mouse appears negative, however, this is due to the low exposure time required
for adjacent mice.
https://doi.org/10.1371/journal.pntd.0007373.g004
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the CNS concentration of administered antibodies. Efficacy against stage 2 infection would be
the next test for ADCs and, if necessary, bifunctional fusion antibodies that can cross the
blood-brain barrier have been described [57].
It is worth contrasting a potential ADC treatment with the current effective drug regimens
for trypanosomiasis. Pentamidine, the current stage 1 T. b. gambiense treatment, is adminis-
tered to patients intramuscularly at 4 mg/kg over 7 days, although it has been shown to clear a
mouse model of T. b. brucei infection at 2.5 mg/kg over four intraperitoneal injections [30,
62]. For stage 2 T. b. gambiense infection, the current nifurtimox eflorithine combination ther-
apy involves oral nifurtimox 15 mg/kg/day for 10 days plus eflornithine infusions 400 mg/kg/
day for 7 days (for a 50 kg adult this is 20 g eflornithine per day) [63]. A single dose of ADC
would clearly be an improvement and provides an alternative approach to small molecule
drugs that may or may not have advantages, in particular in cases or areas where resistance to
small molecules arises.
Considerable resources are being used for the optimisation, assessment and clinical trials of
oncology ADCs. It is difficult to imagine such resources being available for the developmental
pipeline of therapeutics against protozoal pathogens that primarily affect developing countries.
Both cancer and protozoal pathogens are eukaryotic cells and so the oncology-based strategies
that take advantage of the cell biology of cancer cells are often applicable to protozoa. There-
fore, the scope for benefiting from oncology developments is clear, particularly where the drug
(such as PBDs, as used in this study) do not deviate from oncology ADCs that are under devel-
opment. If simply modifying the epitope binding site can allow anti-cancer ADCs to be repur-
posed then they could realistically be developed as a novel class of therapeutics for protozoan
pathogens. The cell surfaces of protozoan pathogens are often particularly well studied due to
the biological interest in their role in host:parasite interactions and therefore the literature con-
tains a reservoir of potential targets (for example [64–68]). It is also worth noting that the pro-
duction cost of ADCs is far less than often realised [69–73] and could be as little as $5 per
human.
In summary, we have demonstrated that a single dose of an ADC, shown to specifically
operate through the HpHbR was able to completely cure an infection in a stage 1 trypanosomi-
asis model. These type of agents have the potential for development for use to treat trypano-
some infection in humans, and in the longer term livestock animals. Furthermore, this work
illustrates that developments in oncology ADCs can be applied to protozoal pathogens, the
causal agents of many neglected diseases in need of new therapeutics.
Materials and methods
Phage display selection of anti-HpHbR N-terminal domain single chain
variable fragments
Recombinant HpHbR N-terminal domain (NTD) was expressed as previously described [34]
and a scFv antibody library was used to perform soluble and panning phage display selections
[74]. Briefly, panning selections were performed by coating 5 μg/mL biotinylated HpHbR
NTD on to a single well of a streptavidin-coated 96-well plate or 10 μg/mL non-biotinylated
HpHbR NTD on to a single well of a Nunc Maxisorp plate overnight at 4˚C. Coated wells were
washed three times with phosphate buffered saline (PBS) prior to incubation for 1hr at room
temperature with 3% Marvel skimmed milk powder in PBS. Next, 1 x 1012 phage particles in
6% Marvel in PBS were added to each coated well and incubated for 1hr at room temperature.
The wells were washed five times with PBS containing 0.1% Tween-20 and five times with PBS
prior to elution and recovery of phage. For soluble selection, phage were pre-incubated with
magnetic beads in 3% Marvel in PBS at room temperature for 1 hour. Subsequently, the
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magnetic beads were removed and the phage-containing supernatant was incubated with bio-
tinylated HpHbR NTD at room temperature for 1 hour. Streptavidin magnetic beads were
subsequently added to the reaction and incubated at room temperature for 5 minutes. The
magnetic beads were washed five times with 0.1% Tween-20 in PBS. For all selections, phage
were eluted with 10 μg/ml trypsin in PBS for 30 minutes at 37˚C. Exponentially grown TG1
E.coli cells were infected with the eluted phage and grown overnight at 30˚C on agar plates
containing ampicillin. E. coli colonies were harvested from the bioassay plates and phage parti-
cles were rescued by super-infecting with M13 KO7 helper phage and used in the next round
of selection. In total, three serial rounds of selection were performed.
Phage ELISA
Individual phage were produced from E. coli and assayed, by phage ELISA, against TbHpHbR
NTD in parallel with BSA and streptavidin. Briefly, 10 μg/ml of each protein was coated onto
Nunc Maxisorp plates and 5μg/mL of each biotinylated protein was coated onto streptavidin-
coated plates overnight at 4˚C. Plates were washed three times with PBS before being incu-
bated with 3% Marvel in PBS for 1 hour at room temperature. Phage containing supernatants
were blocked with an equal volume of 6% Marvel in 2xPBS for 1 hour at room temperature.
Coated plates were washed three times with PBS and incubated with 50 μl of blocked phage
supernatants for 1hr at room temperature. Plates were washed three times with 0.1% Tween 20
in PBS and bound phage were detected using an anti-M13 horseradish peroxidase conjugated
antibody and colorimetric substrate. Rabbit polyclonal anti-TbHpHbR antibody was used as a
positive control and detected with mouse anti-rabbit IgG HRP.
Generation of full length human IgG1 with a cysteine insertion at residue
239 of the heavy chain
Selected scFvs were converted to full length human IgG1s using standard molecular biology
techniques. Secreted antibodies [75] were purified by protein A affinity chromatography.
Recombinant antibody was labelled with Alexa Fluor 594 following the manufacturer’s
instructions (Life Technologies).
PBD conjugation
HpHbR antibodies and a NIP228 negative control were reduced by the addition of a forty fold
molar excess of tris(2-carboxyethyl)phosphine (TCEP) in PBS, 1 mM EDTA, pH 7.2 for 4 h at
37˚C. TCEP was subsequently removed and the disulphides were re-oxidised with a twenty
times molar excess of dehydroascorbic acid for 4h at 25˚C. A ten times molar excess of toxin
plus linker was added and incubated for 1 h at 25 ˚C, the reactions were quenched by the addi-
tion of excess of N-acetyl-L-cysteine. The resultant ADCs were formulated in PBS, pH 7.2 after
ultrafiltration to removed excess toxin. ADCs were characterized by determination of mono-
meric purity by size exclusion chromatography (S2 Table), drug-antibody-ratio (DAR) by RP-
HPLC chromatography (S2 Table) and molecular mass (by LC-MS of the reduced ADCs)
(S5 Fig)
Trypanosome cell culture
T. b. brucei Lister 427 bloodstream cells were grown in HMI-9 salts plus 10% foetal calf serum
(FCS) at 37˚C with 5% CO2 [76]. The T. b. brucei Lister 427 HpHbR -/- cell line used here has
been described previously [34].
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Internalisation of fluorescently labelled IgGs into live cells
For T. b. brucei uptake assays 1 x 106 cells per assay were incubated with 10 nM Alexa Fluor
594-labelled IgG in 300μl HMI-9, 10% FCS, 2μM FMK-024 protease inhibitor for 1.5 hours at
37˚C. Cells were washed once in HMI-9, 10% FCS then fixed in 1% PFA for 10 minutes at
room temperature and resuspended in PBS. Internalisation was determined by microscopy
using a Zeiss Imager M1 microscope and analysed with AxioVision Rel 4.8 software.
In vitro trypanosome cell-killing assays
T. b. brucei Lister 427 wild-type or HpHbR -/- cell lines were incubated at 1 x 104 cells/ml in
triplicate with PBDs or ADCs for 48 hours before cells were counted and growth was calcu-
lated relative to an untreated control for each cell line. All assays contained 0.5% DMSO. Data
were Log10 transformed and nonlinear regression lines of best fit and IC50 values were calcu-
lated using GraphPad Prism 6.
CellTiter-Glo luminescent cell viability assay
In vitro viability cell assays were performed with primary and transformed human cell lines:
Raji (ECACC), Jurkat E6.1 (ATCC), NHLF (LONZA) and HUVEC (LONZA). These cell lines
were mycoplasma tested and authenticated by PCR using human 16-marker short tandem
repeat profiling and interspecies contamination test by IDEXX (Columbia, MO). Cells seeded
at 2 x 105 cell/ml (Raji and Jurkat) and at 2 x 103 cell/ml (NHLF and HUVEC) in 96 well plates
were incubated with the SG3552 toxin, the toxin+linker SG3376 and the corresponding ADCs
(Tb074-SG3376, Tb085-SG3376 and NIP228-SG3376). All assays contained 0.5% DMSO.
After 96 hours, the number of viable cells in culture was measured using the CellTiter-Glo 2.0
luminescent cell viability assay and read in Envision plate reader. Growth was calculated rela-
tive to an untreated control for each cell line. Data were Log10 transformed and nonlinear
regression lines of best fit and IC50 values were calculated, where possible using GraphPad
Prism 6.
Mouse infection and bioluminescent imaging of trypanosome infection
Pleomorphic T. b. brucei GVR35-VSL2 bloodstream forms were cultured and maintained at
37˚C/5%CO2 in HMI-9 medium supplemented with 20% FBS, 1μg/ml puromycin and 1%
methyl cellulose [33]. Parasites were maintained at<1 x 106 ml-1 and were not cultured for
more than three passages prior to mouse infection.
Mice were purchased from Charles River (UK). They were maintained under specific path-
ogen-free conditions in individually ventilated cages with a 12 hour light/dark cycle and access
to food and water ad libitum. Female BALB/c mice aged 8 to 12 weeks were infected intraperi-
toneally with 3x104 T. b. brucei GVR35-VSL2 cells [33]. Three groups of five mice were
infected. On day 3 post infection the mice were imaged to obtain the pre-treatment infection
level. Five mice received 0.25 mg/kg Tb085-SG3376, five mice received PBS alone and five
mice received 0.25 mg/kg NIP288, all intravenously. A group of three mice was not infected.
Imaging was carried out by intraperitoneal injection of 150 mg/kg D-luciferin. After 5 min-
utes, mice were anaesthetised with 2.5% (v/v) gaseous isofluorane in oxygen. The mice were
transferred to the IVIS Illumina and imaged using LivingImage 4.3. software (PerkinElmer).
Exposure times were determined automatically and varied between 0.5 s and 5 min depending
on the radiance. After imaging, mice were allowed to recover and transferred back to their
cages.
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At 66 days post-infection, Tb085-SG3376 treated mice were immunosuppressed with a sin-
gle intraperitoneal dose of cyclophosphamide (200 mg/kg).
Ethics statement
All animal work was performed under UK Home Office licence 70/8207 and approved by the
London School of Hygiene and Tropical Medicine Animal Welfare and Ethical Review Board.
All protocols and procedures were conducted in accordance with the UK Animals (Scientific
Procedures) Act 1986.
Supporting information
S1 Fig. Sequences of the six scFv targeting the HpHbR NTD. The framework domains (FW)
are shown in black and the complementarity-determining regions (CDR1-3) are shown in
blue. Sequence variation between scFvs is in CDR3, as annotated by grey boxes.
(TIF)
S2 Fig. Conjugating toxin SG3552 to antibodies that recognise the T. brucei HpHbR
reduces toxicity against human cell lines. Toxin SG3552, toxin plus linker SG3376 and the
associated ADCs were incubated with (A) Jurkat T-cells, (B) Human Umbilical Vein Endothe-
lial Cells (C) Normal Human Lung Fibroblasts, and (D) Raji B-cell lymphoma cells in FCS.
Toxin SG3552 kills the human cell lines at picomolar concentrations. Killing activity is
reduced in all cell lines by the addition of the linker (SG3376) or incorporation into a control
or Anti-HpHbR ADC (NIP22-SG3376, Tb074-SG3376, Tb085-SG3376) to mid-to-high nano-
molar concentrations. Lines represents nonlinear regression lines of best fit on Log10 trans-
formed data, although it was not possible to fit accurate lines or calculate IC50 values for the
ADCs due to lack of saturation of the cell killing assay. All assays were carried out in triplicate
over 96 hours. Error bars represent s.e.m., n = 3.
(TIF)
S3 Fig. Mass spectrometry analysis of SG3376-containing antibody-toxin conjugates. Mass
spectrometry analysis of reduced antibody-toxin conjugates was performed using a RSLC
UPLC system coupled to an Exactive EMR Orbitrap MS. L0 = unconjugated light chain spe-
cies, H0 = unconjugated heavy chain species, H1 = conjugated heavy chain species.
(TIF)
S4 Fig. Bioluminescent imaging of T. b. brucei infected mice before and after treatment
with antibody-toxin conjugates. Parasite burden in mice infected with pleomorphic T. b. bru-
cei GVR35-VSL2 cells was assessed by BLI following intraperitoneal injection of d-luciferin.
BLI was performed prior to any treatment at 3 days post infection (dpi) and then at regular
time points following treatment on 3 dpi with (1) Tb085-SG3376 (n = 5), (2) NIP228-SG3376
(n = 5) or (3) PBS alone (n = 5), with selected time points shown here. Uninfected mice were
imaged as controls (n = 3). Treatment with Tb085-SG3376 decreased the luminescent signal to
that obtained from uninfected control animals within 2 days and this remained the case for the
duration of the infection, including following the immunosuppression of Tb085-SG3376-
treated mice at 66 dpi. For each group of mice both the dorsal and ventral images are shown.
Scale bar represents the photons emitted at any given point on the image. Exposure times
range from 0.5 seconds (for heavily burdened mice) to 5 minutes (for uninfected animals).
One mouse in the PBS control group had a lower BLI signal than all other infected mice at 3
dpi (S5 Fig). In the image shown here this mouse appears negative, however, this is due to the
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low exposure time required for adjacent mice. Quantification of the total luminescence from
each mouse was also carried out (Fig 4 and S5 Fig).
(TIF)
S5 Fig. A single low dose of Tb085-SG3376 was able to cure infection in a mouse model of
trypanosomiasis: Data from individual mice. Three groups of 5 mice were infected with
pleomorphic T. b. brucei GVR35-VSL2 cells, which allow for parasite burden in live mice to be
assessed over a time course by bioluminescent imaging (BLI). BLI was performed prior to any
treatment at 3 dpi and then at regular time points following treatment on 3dpi with a single
intravenous dose of (1) 0.25 mg/kg Tb085-SG3376 (n = 5), (2) 0.25 mg/kg NIP228-SG3376
(n = 5) or (3) PBS alone (n = 5). Unlike the control-treated mice, Tb085-SG3376 treatment
caused a decrease in the luminescent signal to that obtained from uninfected control animals
within 2 days and this remained the case for the duration of the infection, including following
the immunosuppression of Tb085-SG3376 treated mice at 66 dpi. Mice treated with NIP228-
SG3376 or PBS were culled at a humane endpoint on day 14. Quantification shown is the com-
bined (dorsal + ventral) luminescence over the whole mouse in photons per second (p/s). The
combined quantification data from the 4 groups of mice are shown in Fig 4. Selected images
for the BLI are shown in S5 Fig.
(TIF)
S6 Fig. No parasites were detected by BLI post-necropsy in T. b. brucei infected mice fol-
lowing treatment with Tb085-SG3376. The five mice that were infected with pleomorphic
T. b. brucei GVR35-VSL2 cells, treated with 0.25 mg/kg Tb085-SG3376 (3 dpi) and immuno-
suppressed (66 dpi) were culled at 80 dpi. Post-necropsy, mice corpses and selected organs
were assessed by BLI. Consistent with BLI data from live mice, BLI signal was equivalent to the
uninfected control mice and so image appears black and white due to the total absence of any
luciferase signal.
(TIF)
S1 Table. IC50 values (pM) of SG3199-based toxins and antibody-toxin conjugates against
wild type T. b. brucei. The IC50 values of toxin SG3199, toxin plus linker SG3249, a control
ADC (NIP228-SG3249) and five anti-trypanosome antibody toxin conjugates targeting the T.
brucei HpHbR (Tb017-SG3249, Tb073-SG3249, Tb074-SG3249, Tb078-SG3249, Tb085-
SG3249) were calculated against T. b brucei wild type (Fig 3). Values in bold are best-fit IC50
values, the range is the 95% confidence intervals. All values are shown to 3 significant figures.
(DOCX)
S2 Table. Monomer content and drug-antibody-ratio (DAR) of SG3376-containing Anti-
body-toxin conjugates. Monomeric purity was determined by size exclusion chromatography
(SEC) and the DAR was determined by RP-HPLC. Both assays were performed on a Shimadzu
Nexera UPLC system fitted with a Shimadzu Prominence DAD detector. Data were processed
using LabSolutions software.
(DOCX)
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